China News Service, September 1 (Chen Jing, Wang Guangzhao, Qin Xiaojian) The reporter was informed on the 1st that the "CSCO Guidelines for Diagnosis and Treatment of Prostate Cancer" (hereinafter referred to as the Guidelines), based on the Chinese population's multidisciplinary comprehensive diagnosis and treatment guidelines for prostate cancer, was officially released.
The guide was led by Professor Ye Dingwei, Chairman of the Prostate Cancer Specialty Committee of the Chinese Society of Clinical Oncology and Professor Ye Dingwei from Fudan University Affiliated Cancer Hospital, and was compiled by more than 80 experts from dozens of well-known urinary tumor diagnosis and treatment centers in China.
Professor Ye Dingwei, the leader of the guideline writing group, said in an interview with a reporter from Chinanews.com on the 1st that a "tailor-made" treatment plan based on research data from the Chinese population is available, which means a multidisciplinary, standardized comprehensive treatment of prostate cancer that meets the physiological characteristics of Chinese people. "There are chapters to follow."
It is reported that the prostate cancer diagnosis and treatment guidelines based on Chinese population data are combined with the international consensus on the diagnosis and treatment of prostate cancer, and widely quoted based on the research results of prostate cancer in the Chinese population. The subjects involved cover urology, radiology and diagnostics. Provide a precise and standardized multidisciplinary treatment "model" program for prostate cancer.
Professor Ye Dingwei told reporters that in China, the characteristics of prostate cancer incidence are different from those of European and American countries, and there is a regional imbalance.
It is understood that in recent years, the incidence of prostate cancer in China has been on the rise. Most prostate cancer patients are already in the advanced stage when they are first diagnosed, and the mortality rate is relatively high.
Ye Dingwei said that this contrasts with the characteristics of high early detection rate and low mortality in European and American countries.
The expert pointed out that clinical studies have confirmed that there are differences in tumor types and genetic susceptibility between Chinese prostate cancer and European and American populations.
Therefore, the diagnosis and treatment of prostate cancer is the standard treatment in the eastern and western population?
It should be different.
Ye Dingwei said bluntly that the level of diagnosis and treatment of prostate cancer in China is extremely unbalanced, and most of the current guidelines for the treatment of prostate cancer are derived from research results in Western countries.
It is reported that under the leadership of Professor Ye Dingwei, the Multidisciplinary Team of Urology and Oncology of Fudan University Affiliated Cancer Hospital established a screening system for high-risk groups of prostate cancer based on the "Internet +" technology and promoted it nationwide.
Fudan Cancer Hospital has joined hands with 11 parent triangle regional medical institutions to initially achieve demonstration screening of thousands of high-risk groups of prostate cancer.
Ye Dingwei's team also established a risk model based on a large-scale population cohort to accurately predict high-risk patients with prostate cancer and avoid overdiagnosis and treatment caused by widespread screening.
(Finish)